Remepy
New York, United States
◆ About Remepy
AI-driven Parkinson's treatment company preparing for Phase III clinical trials
◆ What sets it apart
It combines a regulated drug with a personalized, adaptive software protocol in a single therapeutic product, which Remepy describes as a Hybrid Drug.
◆ Sectors
◆ Business
Modelhardware
CustomerParkinson's disease patients and the pharmaceutical partners or clinicians involved in prescribing and validating the Hybridopa therapy
◆ Notable
- Reported statistically significant Phase IIa results for Hybridopa in Parkinson's disease
- Preparing to enter Phase III clinical trials in H2 2026
- Raised $36 million in Series A funding
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Remepy do?
AI-driven Parkinson's treatment company preparing for Phase III clinical trials
Where is Remepy based?
Remepy is based in New York, United States.
How much has Remepy raised?
Remepy has raised $36M in tracked funding and is currently at the series-a stage.
Who has invested in Remepy?
Investors in Remepy include OG Venture Partners, M Ventures, NFX, Qumra Capital, Tadmor Group, TechAviv and Vine Ventures.